Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
SAN FRANCISCO and SUZHOU, China, June 3, 2021 /PRNewswire/ Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality. | June 3, 2021
Share this article
Share this article
SAN FRANCISCO and SUZHOU, China, Jan. 11, 2021 /PRNewswire/ Innovent Biologics, Inc. ( Innovent , HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced with Eli Lilly and Company ( Lilly ,NYSE: LLY) that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) as second-line therapy for squamous non-small cell lung cancer (sqNSCLC). The application is the third sNDA for TYVYT® (sintilimab injection) in NSCLC.
This sNDA was based on a randomized, open-label, Phase 3 clinical trial (ORIENT-3) evaluating TYVYT® (sintilimab injection) as second-line therapy for patients with advanced or recurrent sqNSCLC whose cancer had progressed on first-line platinum-based chemotherapy. Based on the